New Pet Tracers for Cerebral Dopamine: Should 6-[18F]Fluoro-L-Dopa be Replaced?

Firnau, G.; Chirakal, Raman; Wahl, Lindi M.; Chen, Jia Juen; Murthy, Dilip; Nahmias, Claude; Garnett, E. S.

doi:10.1007/978-1-4757-9670-4_26

Chemists’ Views of Imaging Centers 1995

DOI: 10.1007/978-1-4757-9670-4_26

|View full text |Cite

New Pet Tracers for Cerebral Dopamine: Should 6-[18F]Fluoro-L-Dopa be Replaced?

G. Firnau

Raman Chirakal

Lindi M. Wahl

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FMT PET has been used widely in nonhuman primate models of PD but infrequently in human studies. In the past, dosimetry data from studies in which carbidopa pretreatment was not used have limited the dose of FMT to 2.5 mCi to keep bladder wall exposure under 5 rads 7. Although some previous studies have used 5 mCi of FMT in humans,8, 9 others have used 2.5 mCi 10, 11.…”

mentioning

confidence: 99%

A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease

Gallagher¹,

Christian²,

Holden³

et al. 2011

Movement Disorders

View full text Add to dashboard Cite

Progression of Parkinson’s disease symptoms is imperfectly correlated with positron emission tomography biomarkers for dopamine biosynthetic pathways. The radiopharmaceutical 6-[18F]fluoro-m-tyrosine is not a substrate for catechol-O-methyltransferase and therefore has a more favorable uptake-to-background ratio than 6-[18F]fluoro-l-dopa. The objective of this study was to evaluate 6-[18F]fluoro-m-tyrosine relative to 6-[18F]fluoro-l-dopa with partial catechol-O-methyltransferase inhibition as a biomarker for clinical status in Parkinson’s disease. Twelve patients with early-stage Parkinson’s disease, off medication, underwent Unified Parkinson Disease Rating Scale scoring, brain magnetic resonance imaging, and 3-dimensional dynamic positron emission tomography using equivalent doses of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-l-dopa with tolcapone, a catechol-O-methyltransferase inhibitor. Images were realigned within subject, after which the tissue-derived uptake rate constant was generated for volumes of interest encompassing the caudate nucleus, putamen, and subregions of the putamen. We computed both bivariate (Pearson) and partial (covariate of age) correlations between clinical subscores and tissue-derived uptake rate constant. Tissue-derived uptake rate constant values were correlated between the radiopharmaceuticals (r = 0.8). Motor subscores were inversely correlated with the contralateral putamen 6-[18F]fluoro-m-tyrosine tissue-derived uptake rate constant (|r| > 0.72, P < .005) but not significantly with the 6-[18F]fluoro-l-dopa tissue- derived uptake rate constant. The uptake rate constants for both radiopharmaceuticals were also inversely correlated with activities of daily living subscores, but the magnitude of correlation coefficients was greater for 6-[18F]fluoro-m-tyrosine. In this design, 6-[18F]fluoro-m-tyrosine uptake better reflected clinical status than did 6-[18F]fluoro-l-dopa uptake. We attribute this finding to 6-[18F]fluoro-m-tyrosine’s higher affinity for the target, l-aromatic amino acid decarboxylase, and the absence of other major determinants of the uptake rate constant. These results also imply that l-aromatic amino acid decarboxylase activity is a major determinant of clinical status.

show abstract

mentioning

confidence: 99%

A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease

Gallagher¹,

Christian²,

Holden³

et al. 2011

Movement Disorders

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

New Pet Tracers for Cerebral Dopamine: Should 6-[18F]Fluoro-L-Dopa be Replaced?

Cited by 1 publication

References 26 publications

A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease

A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease

Contact Info

Product

Resources

About